Pipeline

CYAD-211 is a short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR complex.

CYAD-211 is currently being evaluated, following Cyflu chemotherapy, in the Phase 1 IMMUNICY-1 trial for the treatment of relapsed/refractory multiple myeloma.

CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology to knockdown the expression of NKG2D ligands MICA and MICB on the CAR T cells. In preclinical models, shRNA-mediated knockdown of MICA and MICB expression on NKG2D CAR T cells has shown enhanced in vitro expansion, as well as enhanced in vivo engraftment and persistence, of the CAR T cells, as compared to first-generation NKG2D-based CAR T cells.

In December 2021, the Company presented clinical results from the dose-escalation CYCLE-1 Phase 1 trial evaluating CYAD-02 for the treatment of relapsed or refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).